Novel Perspective for Antithrombotic Therapy in TAVI-Reference-Cited by-同舟云学术

Novel Perspective for Antithrombotic Therapy in TAVI

Published:2020-07-14 Issue:23 Volume:26 Page:2789-2803
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

Drakopoulou Maria¹^ORCID,Soulaidopoulos Stergios¹,Oikonomou George¹^ORCID,Stathogiannis Konstantinos¹^ORCID,Latsios George¹^ORCID,Synetos Andreas¹,Tousoulis Dimitrios¹^ORCID,Toutouzas Konstantinos¹^ORCID

Affiliation:

1. First Department of Cardiology, Hippokration Hospital, Medical School of Athens University, Athens, Greece

Abstract

: While surgical aortic valve replacement (SAVR) was for years the only available treatment for symptomatic aortic stenosis, the introduction of transcatheter aortic valve implantation (TAVI) in 2002 and the improvement of its technical aspects in the following years, has holistically changed the synchronous therapeutic approach of aortic valve stenosis. Recent evidence has expanded the indication of TAVI from high to lower surgical risk populations with symptomatic aortic stenosis. The administration of antithrombotic therapy periprocedurally and its maintenance after a successful TAVI is crucial for the prevention of complications and affects postprocedural survival. Randomized controlled trials investigating the appropriate combination and the duration of antithrombotic treatment after TAVI are for the moment scarce. This review article sheds light on the underlying pathogenetic mechanisms contributing in periprocedural TAVI thrombotic complications and discuss the efficacy of current antithrombotic policies as evaluated in randomized trials.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Reference125 articles.

1. Baumgartner H.; Aortic stenosis: medical and surgical management. Heart 2005,91(11),1483-1488

2. Smith C.R.; Leon M.B.; Mack M.J.; Miller D.C.; Moses J.W.; Svensson L.G.; Tuzcu E.M.; Webb J.G.; Fontana G.P.; Makkar R.R.; Williams M.; Dewey T.; Kapadia S.; Babaliaros V.; Thourani V.H.; Corso P.; Pichard A.D.; Bavaria J.E.; Herrmann H.C.; Akin J.J.; Anderson W.N.; Wang D.; Pocock S.J.; Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med PARTNER Trial Investigators2011,364(23),2187-2198

3. Reardon M.J.; Van Mieghem N.M.; Popma J.J.; Kleiman N.S.; Søndergaard L.; Mumtaz M.; Adams D.H.; Deeb G.M.; Maini B.; Gada H.; Chetcuti S.; Gleason T.; Heiser J.; Lange R.; Merhi W.; Oh J.K.; Olsen P.S.; Piazza N.; Williams M.; Windecker S.; Yakubov S.J.; Grube E.; Makkar R.; Lee J.S.; Conte J.; Vang E.; Nguyen H.; Chang Y.; Mugglin A.S.; Serruys P.W.; Kappetein A.P.; Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med SURTAVI Investigators2017,376(14),1321-1331

4. Mack M.J.; Leon M.B.; Thourani V.H.; Makkar R.; Kodali S.K.; Russo M.; Kapadia S.R.; Malaisrie S.C.; Cohen D.J.; Pibarot P.; Leipsic J.; Hahn R.T.; Blanke P.; Williams M.R.; McCabe J.M.; Brown D.L.; Babaliaros V.; Goldman S.; Szeto W.Y.; Genereux P.; Pershad A.; Pocock S.J.; Alu M.C.; Webb J.G.; Smith C.R.; Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med PARTNER 3 Investigators2019,380(18),1695-1705

5. Khatri P.J.; Webb J.G.; Rodés-Cabau J.; Fremes S.E.; Ruel M.; Lau K.; Guo H.; Wijeysundera H.C.; Ko D.T.; Adverse effects associated with transcatheter aortic valve implantation: a meta-analysis of contemporary studies. Ann Intern Med 2013,158(1),35-46

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bicuspid Aortic Valve Disease: From Pathophysiology to Treatment;Journal of Clinical Medicine;2024-08-23

2. Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review;Journal of Cardiovascular Development and Disease;2023-03-23

3. Direct Oral Anticoagulants (DOACs) are Non-Inferior to Vitamin K Antagonists for Patients Undergoing Transcatheter Aortic Valve Replacement with Indications of Anticoagulation;Reviews in Cardiovascular Medicine;2022-10-17

4. Current Antithrombotic Therapy: Beyond Coronary Artery Disease;Current Pharmaceutical Design;2020-07-14